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Introduction
Publishing health research is a thriving, and increasing,
enterprise. On any given month about 63,000 new articles are
indexed in PubMed, the United States National Library of
Medicine’s public access portal for health-related publications.
However, the quality of reporting in most health care journals
remains inadequate. Glasziou and colleagues [1] assessed
descriptions of given treatments in 80 trials and systematic reviews
for which summaries were published during one year (October
2005 to October 2006) in Evidence-Based Medicine, a journal that is
aimed at physicians working in primary care and general
medicine. Treatment descriptions were inadequate in 41 of the
original published articles, which made their use in clinical
practice difficult if not impossible to replicate. This is just one of
numerous examples of a large and disturbing literature indi-
cating the general failure in the quality of reporting health
research [2–6]. Many publications lack clarity, transparency, and
completeness in how the authors actually carried out their
research.
Inadequate reporting is problematic for several reasons. If
authors do not provide sufficient details concerning the conduct of
their study, readers are left with an incomplete picture of what was
done. As such, they are not able to judge the reliability of the
results and interpret them. There are also ethical and moral
reasons for reporting research adequately [7].
The EQUATOR (Enhancing the QUAlity and Transparency
Of health Research) Network is a new international initiative
seeking to improve the quality of scientific publications by
promoting transparent and accurate reporting [8]. The Network
(http://www.equator-network.org) provides resources and training
relating to the reporting of health research and assists in the
development, dissemination, and implementation of reporting
guidelines. As part of its initial resource development, the
Network’s Web site contains a comprehensive and up-to-date
database of reporting guidelines relevant to heath research. A
recent systematic review of 81 reporting guidelines found their
development was often inadequate [9].
Reporting guidelines need to be differentiated from other efforts
that produce a checklist or other guidance not specific to reporting
research. We propose here a working definition of a reporting
guideline: a checklist, flow diagram, or explicit text to guide authors in
reporting a specific type of research, developed using explicit methodology.
Some reporting guidelines recommend a flow diagram so that
authors can clearly report information about sequential stages of
their research project. A consensus process [10] should be a crucial
characteristic of developing a reporting guideline.
The main motivation for the development of reporting
guidelines is to help researchers improve the completeness and
transparency of their research reports and limit the number of
poorly reported studies. However, reporting guidelines can be also
used by peer reviewers and editors to strengthen manuscript
review. And research funders can benefit from introducing
reporting guidelines into the research application system [11].
Ensuring clear and complete reporting of funded research through
the use of reporting guidelines should facilitate more efficient use
of the new findings and bring better returns on research
investments. There are enormous potential benefits of good
reporting. However, despite the impressive recent upsurge in the
number and range of reporting guidelines, the literature on how
individual guidelines were developed remains sparse [12,13] and
there is no generic guidance on how to develop one.
In this paper we update and expand upon an earlier effort to
outline a strategy for developing reporting guidelines that was
published only in Spanish [14]. We recognize that there is no
single best or correct approach. However, this paper benefits from
our collective experiences of helping to develop more than ten
reporting guidelines over the last 16 years, over which period these
ideas have evolved considerably. If reporting guidelines are to be
useful and more widely disseminated, they need to be developed
using robust and widely accepted methodologies.
This strategy assumes the involvement of an executive group to
facilitate the guideline development and the expectation of having
a face-to-face meeting as part of the reporting guideline
development. We propose 18 steps to occur in five phases, which
are outlined in Table 1.
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1. Identify the Need for a Guideline
Developing a reporting guideline is complex and time
consuming, so a compelling rationale is needed. Most reporting
guidelines have been developed because researchers are convinced
of the need to improve the quality of reporting of a certain type of
health research. For some study aspects there may be direct
evidence that inadequate reporting is associated with biased
reports or harmful consequences. At this early stage, the executive
group needs to set out clearly and explicitly their objectives and
consider the scope of recommendations. For example, an early
decision of the STROBE (STrengthening the Reporting of
OBservational studies in Epidemiology) group was to restrict
consideration to three main epidemiological study designs [15],
leaving the way open to extension guidelines dealing with other
designs, such as STREGA (STrengthening the REporting of
Genetic Association Studies) [16].




Initial steps 1 Identify the need for a guideline
1.1 Develop new guidance
1.2 Extend existing guidance
1.3 Implement existing guidance
2 Review the literature
2.1 Identify previous relevant guidance
2.2 Seek relevant evidence on the quality of reporting in published research articles
2.3 Identify key information related to the potential sources of bias in such studies
3 Obtain funding for the guideline initiative
Pre-meeting activities 4 Identify participants
5 Conduct a Delphi exercise
6 Generate a list of items for consideration at the face-to-face meeting
7
a Prepare for the face-to-face meeting
7.1 Decide size and duration of the face-to-face meeting
7.2 Develop meeting logistics
7.3 Develop meeting agenda
7.3.1 Consider presentations on relevant background topics, including summary of evidence
7.3.2 Plan to share results of Delphi exercise, if done
7.3.3 Invite session chairs
7.4 Prepare materials to be sent to participants prior to meeting
7.5 Arrange to record the meeting
The face-to-face consensus meeting itself 8
a Present and discuss results of pre-meeting activities and relevant evidence
8.1
a Discuss the rationale for including items in the checklist
8.2 Discuss the development of a flow diagram
8.3
a Discuss strategy for producing documents; identify who will be involved in which activities; discuss
authorship
8.4 Discuss knowledge translation strategy
Post-meeting activities 9
a Develop the guidance statement
9.1 Pilot test the checklist
10 Develop an explanatory document (E&E)
11 Develop a publication strategy
11.1 Consider multiple and simultaneous publications
Post-publication activities 12
a Seek and deal with feedback and criticism
13
a Encourage guideline endorsement
14 Support adherence to the guideline
15 Evaluate the impact of the reporting guidance
16 Develop Web site
17 Translate guideline
18 Update guideline
aCore items (see text).
doi:10.1371/journal.pmed.1000217.t001
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need exists to develop a new reporting guideline or to extend or
implement an existing guideline.
1.1. Develop new guidance. Developing a new reporting
guideline assumes that there is no existing guideline on the topic
under consideration. The development of STARD (STAndards
for Reporting of Diagnostic accuracy), a reporting guideline for
diagnostic accuracy studies, was undertaken because no guidance
in this area existed previously and evidence suggested the need for
one [17].
1.2. Extend existing guidance. Sometimes there may be the
view that an existing broad guideline can usefully be augmented
by additional guidance for a specific set of studies. An example of
such an extension is the recently published CONSORT (CON-
solidated Standards Of Reporting Trials) for nonpharmacological
treatments (CONSORT for NPT) [18]. Here we felt that there
were specific issues for some types of trials (e.g., surgical) for which
sufficient guidance was not offered in the original CONSORT
publications. The NPT extension still considers the original 22-
item CONSORT checklist as a minimum set of criteria to consider
when reporting a randomized controlled trial (RCT), but it
extends 11 of these items for further consideration when reporting
a trial that has used an NPT intervention.
1.3. Implement existing guidance. Most guidelines are
defined by the study aims and methodology, leaving plenty of
scope to illustrate their implementation in particular medical
specialties. For example, recently a group implemented the
CONSORT Statement for behavioral medicine [19], although
this implementation was not done in collaboration with the
CONSORT Group. Such implementations will generally include
requests for additional topic-specific information. The distinction
between an extension and an implementation can be unclear.
2. Review the Literature
2.1. Identify previous relevant guidance. At this early
stage, prospective guideline developers should search for any
existing reporting guideline covering all or part of the area being
considered. We developed a search strategy to identify and
characterize reporting guidelines as part of an ongoing project. In
addition to electronic searching, developers are encouraged to
search the EQUATOR Network database of reporting gui-
delines (http://www.equator-network.org). We recommend that
reporting guideline developers interested in extending or
implementing an existing guideline contact the authors and
discuss their plans.
2.2. Seek relevant evidence on the quality of reporting in
published research articles. We recommend searching for
relevant evidence on the quality of reporting of published research
articles within the domain of interest. Such reports provide an
initial and important insight into the items to consider for inclusion
in an eventual checklist and potential stakeholders to invite to a
meeting. However, this literature can be elusive and appear in any
journal. A more thorough process, such as a systematic review,
would be useful here. The existence of such literature can be most
readily ascertained by conducting comprehensive electronic
searches of several databases. In preparing for the 2005
QUOROM (QUality Of Reporting Of Meta-analyses) meeting,
among other activities we conducted a systematic review of studies
that had reviewed the quality of reporting of systematic reviews.
To help inform updating of the CONSORT Statement we search
the literature every month for new studies of the reporting of
randomized trials.
2.3. Identify key information related to the potential
sources of bias in relevant studies. For any guideline, both
new and revised, there will be key pieces of information that must
be included. For example, in a 1993 meeting that ultimately led to
the development of the CONSORT Statement, we identified
emerging empirical data on the importance of the methods and
reporting of allocation concealment when describing the ran-
domization process [20]. The 2010 update of the CONSORT
Statement includes new checklist items on identifying any changes
to trial outcomes after the trial commenced, and on trial
registration. The new item on outcomes follows from empirical
evidence [21] indicating that authors frequently do not provide
analyses of outcomes in their published papers that were the pre-
specified outcomes in their protocols (i.e., selective outcome
reporting). The addition of a new trial registration item reflects
current journal practice [22] stemming from some researchers
hiding results of randomized trials [23].
3. Obtain Funding for the Guideline Initiative
To date, no published data inform the costs required to develop
a reporting guideline. Even if funding is available, most developers
limit their fiscal requests to cover only the main reporting
guideline meeting. In our experience, considerable resources are
required for pre-meeting activities, such as literature searching and
conducting a Delphi exercise, and post-meeting activities,
including the need for a small writing group to be able to meet
in person, perhaps on several occasions, during the drafting of the
guidance and development of an explanation and elaboration
(E&E) document.
Depending on the extent of the pre-meeting activities we
recommend allocating at least Can$10,000 for them. In our
experience the main meeting costs are approximately Can$75,000.
This covers the travel and accommodation costs of bringing
together 20 to 30 participants. For new guidance in the form of a
checklist, with a more detailed and extensive E&E, we recommend
at least Can$35,000 for a small writing group to meet several
times.
There is no obvious choice as to where reporting guideline
developers can seek funding; we are unaware of any granting
agency or other group that has a specific remit to provide funding
to those interested in improving ways to report health research. Of
the 30 respondents to our survey [24], 47% had received funds
from a non-profit agency, 17% from the pharmaceutical industry,
and 6% from government. We recommend that developers seek
funds from all of these sources.
Pre-meeting Activities
4. Identify Participants
Most reporting guidelines have been developed by an
international multidisciplinary group involving 22 (median) people
[24], although not all may participate in meetings. The expertise
of these individuals should reflect the particular guidance under
consideration; participants will usually include statisticians,
epidemiologists, methodologists, content experts, journal editors,
and perhaps consumer representatives. The proportion of content
experts needs to be at least a quarter, and perhaps larger
depending on the content area under consideration. When
developing the herbal extension of the CONSORT Statement
we included pharmacognosy experts to provide input on several
issues pertinent to reporting herbal interventions.
Well ahead of the proposed meeting date, a list of participants to
invite should be developed. The CONSORT executive has
typically invited participants in a two-stage process. First, we
identify a small group of invitees whose participation we consider
essential to hold a meeting. We invite this small group
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has been settled we invite the remaining participants. We also keep
an additional smaller list of people to consider inviting should
some second-wave invitees not be able to participate in the
meeting. We recommend sending out the meeting invitations well
in advance, ideally six months before the meeting date.
5. Conduct a Delphi Exercise
Not all potential meeting participants can be invited or will be
able to come to the main guideline development meeting. These
people can still be engaged in the guideline development process.
The CONSORT group has started using a Delphi consensus
method [25] to achieve this goal. The Delphi method is a
structured process of obtaining information from a group of
experts by means of a series of questionnaires, each one refined
based on the feedback from respondents on a previous version
[10].
To help develop CONSORT for RCT abstracts, we used a
three-stage Delphi process. Journal editors, health care profes-
sionals, methodologists, clinical trialists, and others with expertise
in the reporting of RCTs (n=109) who were known to have an
interest in the reporting of randomized trials, the structure of
abstracts, or both were invited by e-mail to participate in a Web-
based survey and rate the importance of 27 suggested checklist
items selected from previous research. During three rounds of the
survey, participants were asked about their views on the relative
importance of the possible checklist items [25].
6. Generate a List of Items for Consideration at the
Face-to-Face Meeting
There is no best way to generate the list of items for
consideration, which will likely come from a number of sources,
such as the Delphi process discussed above (see item 5). For
example, the Delphi process for the SPIRIT (Standard Protocol
Items for RandomIzed Trials) meeting resulted in 63 nominated
items to consider for inclusion in the checklist discussed during the
face-to-face consensus meeting. The executive may reduce the
initial list of items to a more manageable number for discussion
during the face-to-face meeting (see item 8).
7. Prepare for the Meeting
7.1. Decide size and duration of the face-to-face
meeting. Regardless of the available funding we recommend
keeping the size of the meeting to no more than about 30
participants. Larger meetings can lose their spontaneity and limit
interaction among the participants, both important attributes of a
successful meeting. The CONSORT for herbal medicines meeting
was small, involving 16 participants. In contrast, the CONSORT
for NPT meeting was large, at 32 participants. Here we were
interested in many types of interventions, such as surgery and
psychotherapy, requiring a broader number of clinical content
experts. It is valuable to have several people who have participated
in previous similar meetings.
Reporting guideline meetings that we have been involved in
have lasted from one to three days. We recommend a minimum of
one day for developing a reporting guideline regardless of whether
the guidance is new, an implementation, or an extension.
7.2. Develop meeting logistics. The successful planning
and implementation of any reporting guideline meeting requires
thorough organization. If funding permits a coordinator should be
hired to organize the meeting, including venue selection, meal
plans, participant travel and accommodation, and finances.
7.3. Develop meeting agenda. The executive must develop
the form and structure of the meeting to ensure adequate time to
discuss all of the agenda items. The most important outcome of the
face-to-face meeting is an early version of the guidance checklist.
We recommend that the following points be considered as part of
developing the meeting agenda.
7.3.1. Consider presentations on relevant background
topics, including summary of evidence. A useful way to set
the stage and maximize participant dialogue is to devote at least a
few hours to presentations on topics underpinning the reporting
guideline development. Presentations might also be usefully
devoted to specific items that are being proposed for the
checklist and any relevant empirical evidence.
Ideally, by the conclusion of this session all participants should
have up-to-date knowledge about the quality of reporting of the
literature at which the guidance is aimed and the evidence relevant
to considering the merits of including specific checklist items.
Some of this material can be circulated in advance, but it is
unlikely that people have time to read extensive materials. A major
advantage of the Delphi exercise is that participants can think
about some key issues before the meeting.
7.3.2. Plan to share results of Delphi exercise, if
done. We have found that a Delphi exercise provides
important information when developing a reporting guideline,
regardless of whether the guidance is new, an extension, or
implementation. The results of a Delphi exercise were presented
to participants during the first day of the following three
meetings: CONSORT for abstracts, CONSORT for NPT, and
SPIRIT.
7.3.3. Invite session chairs. The main meeting will most
likely be divided into sessions. While some of the chairs of sessions
should be members of the executive group, other participants
should also be invited to chair sessions, particularly if they
have previous experience developing reporting guidelines and/
or chairing meetings. It is essential that chairs have known
ability to handle sessions effectively, to ensure that decisions are
made.
7.4. Prepare materials to be sent to participants prior
to meeting. We recommend sending some materials to
participants before the meeting, even though the same materials,
and additional ones, should be readily available for each
participant during the meeting. Sending the meeting agenda,
participant list, one or two papers that might best highlight the
quality of reporting of the content area, and the results of any
Delphi exercise, if done, is a useful minimum and should be sent to
the participants at least a week ahead of the meeting.
7.5. Arrange to record the meeting. The options include
audio (and possibly visual) recording of the entire event (this
has proved valuable), hiring someone to take comprehensive
minutes, or a combination of both. Depending on the meeting
agenda, a more focused recording and/or minuting of certain
parts of the meeting is another option. As a minimum we
recommend comprehensive minuting of all discussions specifically
related to the checklist development. Such minuting provides all
participants with a record of events and decisions taken during the
meeting.
The Face-to-Face Consensus Meeting Itself
The meeting should follow closely the pre-meeting plans,
although timings should be flexible. It is unlikely that all the
participants will know each other, so it is helpful for everyone to
introduce themselves and indicate the relevance of their particular
experience. One of the first tasks of the meeting is to review the
objectives and the way the meeting will run, and to clarify any
outstanding issues among the participants.
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and Relevant Evidence
The substantive meeting begins with any formal presentations of
background topics, empirical evidence from the literature, and
results of any Delphi process (see item 5 above).
8.1. Discuss the rationale for including items in the
checklist. The most detailed and structured discussions at the
meeting revolve around which checklist items to include in the
guideline; these discussions should focus on information content
and not get distracted by seeking agreed wording at this stage. We
have always considered the items included in a checklist to be a
minimum essential set of items that should be reported, and some
discussion of this perspective is valuable before the detailed
discussions begin.
The inclusion of each item is ideally supported by empirical
evidence, when available. For example, the inclusion of allocation
concealment as a checklist item of the original CONSORT
Statement was based on an empirical study [20]. There are few
such cases. More often there is a consensus that the information is
methodologically important to assess in a study; there may also be
good evidence that it is frequently not reported. Similarly, evidence
and/or conceptual importance in one domain may be transferable
from one guideline to another. For example, a specific checklist
item on trial registration has been added to the CONSORT 2010
Statement. Similarly, during the 2005 QUOROM meeting we
agreed to include a checklist item requesting that authors provide
registration information about their systematic review, if available
[26]. There may be other reasons for a focused discussion about
the inclusion of an item. For example, the CONSORT Statement
requests that the study be identified in the title as a randomized
trial to aid searching for such studies.
The views expressed in a Delphi exercise, and perhaps also how
similar issues were handled in other reporting guidelines, are also
important. Ultimately the views of the meeting participants will
usually converge, although it may occasionally be necessary to vote
on some issues. We recommend considering a classification
scheme for selecting items for inclusion in the checklist; we
provide an example of this approach that we’ve used for including
items in the CONSORT checklist (see Table 2).
8.2. Discuss the development of a flow diagram. The
majority of reporting guidelines have been limited to developing a
checklist [24]; a few groups have also developed a flow diagram,
the most well known of which is the CONSORT diagram. We
recommend that the meeting agenda include discussion of the
possibility of developing a diagram and, if appropriate, consi-
deration of its content.
8.3. Discuss strategy for producing documents; identify
who will be involved in which activities; discuss
authorship. The most important deliverable is the final
reporting guideline. Commonly this will be in the form of a
journal article, written after the meeting that introduces the
checklist (and flow diagram) and summarises the processes used to
develop it. Some groups such as CONSORT refer to this
document as a ‘‘Statement’’ to distinguish it from other types of
publication. A detailed explanatory paper, an E&E, may also need
consideration. Sufficient time needs to be included in the meeting
agenda to discuss these activities. Developing an E&E is very time
consuming, and will require further input from the meeting
participants (see item 10). To accomplish this task we have often
asked meeting participants, all of whom would be considered for
authorship, to volunteer to help draft particular sections. Time
needs to be set aside to discuss these issues during the meeting and
the authorship model needs to be agreed upon.
8.4. Discuss knowledge translation strategy. One of the
last major sessions of the meeting should be devoted to issues
pertaining to disseminating the reporting guideline. There are
several points to consider here, especially a publication strategy.
Since the simultaneous publication in three journals of the 2001
CONSORT Statement, several reporting guidelines have been
published in multiple journals. Ultimately reporting guideline
developers want to positively influence the reporting of health
research and will need to consider how best to ask journals and
editorial groups (such as the International Committee of Medical
Journal Editors), for help achieving these goals. To address these
issues adequately the PRISMA (Preferred Reporting Items for
Table 2. Classification of categories of items for consideration for inclusion in a reporting guideline checklist, illustrated by some
items from the CONSORT checklist.
Item Item Classification CONSORT Checklist Number
Allocation concealment An item that is not conducted properly is
associated with empirical evidence of bias
9. Mechanism used to implement the random allocation sequence (e.g.,
sequentially numbered containers), describing any steps taken to conceal the
sequence until interventions were assigned
Blinding An item that is not adequately reported is
associated with empirical evidence of bias
11a. If done, who was blinded after assignment to interventions (e.g.
participants, care providers, those assessing outcomes) and how
11b. If relevant, description of the similarity of interventions and procedures
Sample size An item that might not have direct bearing
on eliminating bias in the trial’s design, but
obviously influences its success
7a. How sample size was determined
7b. When applicable, explanation of any interim analyses and stopping
guidelines
Numbers analyzed An item that reflects upon trial conduct and
impacts upon internal and external validity
16. For each group, number of participants (denominator) included in each
analysis and whether the analysis was by original assigned groups
Outcomes and estimation An item that reflects the crucial trial results 17a. For each primary and secondary outcome, results for each group, and the
estimated effect size and its precision (e.g., 95% confidence interval)
17b. For binary outcomes, presentation of both absolute and relative effect sizes
is recommended
Participants An item that is essential for external validity
(generalisability, applicability)
4a. Eligibility criteria for participants
4b. Settings and locations where the data were collected
Interpretation An item that aids in the interpretation of the
results
22. Interpretation consistent with results, balancing benefits and harms, and
considering other relevant evidence
doi:10.1371/journal.pmed.1000217.t002
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member dissemination committee. How to maximize journal
endorsement and adherence to the reporting guideline can also be
discussed during the meeting. Additional points for discussion can
include: whether and how the guidance will be formally evaluated;
how any criticism will be handled; and whether to create a Web
site and what it might contain.
Post-meeting Activities
Together with drafting and finalizing guideline documents the
reporting guideline developers need to consider their implemen-
tation strategy, including publication issues (open access, copy-
right, peer review, and multiple and possibly simultaneous
publications), website development, and seeking or monitoring
endorsement of and adherence to the reporting guideline.
9. Develop the Guidance Statement
We recommend that initial efforts be focused on drafting the
checklist for the proposed reporting guideline. Efforts aimed at
extending or implementing existing reporting guidelines should
make very clear which parts of their checklist remain the same as
the original and which items have been modified or added. The
process of developing the checklist is very likely to require several
iterations. Initially, this entails taking the discussions from the face-
to-face meeting (item 8.1 above) and crafting each item into a
crisply and unambiguously worded checklist item. The most
appropriate order for the checklist items also needs consideration.
For a new reporting guideline we recommend a short document
of about 2,000 words reporting on the rationale for developing the
guidance and the development process, including a brief
description of the meeting and participants involved. The article
will include the checklist and flow diagram, if developed. In our
experience drafting the checklist and article is best done by a small
writing group made up primarily of members of the executive
team and perhaps one or two others. This group will usually
constitute the guideline authors on behalf of the reporting
guideline group, although group authorship may be preferred.
For extending an existing reporting guideline a similar approach is
recommended. Whether a new guideline is being developed or an
existing one is being extended, the full guideline group will need to
sign off on the document’s content prior to journal submission.
9.1. Pilot test the checklist. Pilot testing the checklist and
flow diagram is worth considering. During the development of the
QUOROM Statement, two members of the executive group
independently asked two separate sets of students taking a
systematic review course for their feedback on the checklist that
was used to help report their systematic review. Their comments
were incorporated into the checklist revisions.
10. Develop an Explanatory Document (E&E)
To date most reporting guidelines have not been accompanied
by a detailed justification and explanation of the recommendations
(e.g., STRICTA [STandards for Reporting Interventions in
Controlled Trials of Acupuncture]). However, we believe that it
is vitally important to provide an explanation of the rationale and
evidence for a guideline item’s inclusion and an elaboration on the
details of an item, hence the title Explanation and Elaboration, or
E&E, adopted by CONSORT and several other groups.
While there will undoubtedly be an urge to complete all of the
guideline revisions rapidly and submit the paper for publication
consideration, we recommend holding off doing so until an E&E
has been prepared (see Box 1). The E&E will be considerably
longer than the guideline statement (probably 10,000–20,000
words). As with the short guideline statement (see item 13) the full
guideline group will need to sign off on the E&E’s content before
journal submission.
We feel that simultaneous publication of the statement along
with an E&E is the most important way to disseminate the work of
the reporting guideline group. For limited extensions a single
article may best cover both roles, as was done, for example, for
CONSORT for herbal interventions [27] and CONSORT for
NPT [18].
11. Develop a Publication Strategy
We recommend that guideline developers negotiate a copyright
agreement to retain the rights of the contents of the statement and
related documents, such as the E&E. We have not found journals
to be resistant to this idea. Similarly, we recommend developers to
negotiate being able to put the reporting guideline on a dedicated
website.
11.1. Consider multiple and simultaneous publications.
Starting with the revised CONSORT Statement in 2001, several
developers have published their guidance in multiple journals
simultaneously to enhance the uptake and dissemination of their
reporting guideline (STARD, STROBE, STREGA, PRISMA). For
Box 1. The Rationale for Developing an
Explanatory Document (E&E) to Support a
Reporting Guideline
A reporting guideline gives a set of recommendations
regarding the information that should be included in the
report of a research study. It may also include guidance on
how some information may best be presented (e.g., in a
Table, or as absolute numbers).
Guideline developers aim to persuade editors and authors
of the importance of adhering to their recommendations.
To that end, simply providing a list of requirements, often
as a checklist, is unlikely to be sufficient. Such a terse
presentation may seem to make unsupported, even
dogmatic statements without clear support, even when
supported by relevant references to other publications.
That concern underpinned the decision of the CONSORT
Group to accompany the revised CONSORT Statement [44]
with a detailed explanatory document, which was named
‘‘Explanation and Elaboration’’ (E&E) [45].
The E&E was intended to provide detailed rationales for all
of the items in the CONSORT checklist and flow diagram.
For each item, the paper included (a) an example of good
reporting from a published paper, (b) the scientific
background and rationale for including that information
in a published article, (c) empirical evidence of bias
associated with the way that aspect of a study is
conducted or reported, and (d) any evidence relating to
the extent of inadequate reporting of that information. In
addition, some fundamental concepts that underpinned
several of the items were discussed in boxes.
The novel format of the CONSORT E&E was emulated for
several later reporting guidelines—STARD, STROBE, and
PRISMA [46–48]. The broad format was retained with little
modification, although the later examples have included
rather more explanatory boxes; for example, the STROBE
paper has eight boxes, including those addressing missing
data, bias, interaction (effect modification), and how to use
the paper. For some guidelines, notably some extensions
of the CONSORT Statement, the explanatory information
has been included with the reporting recommendations in
a single article (e.g., CONSORT cluster [49], NPT [18]).
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studies is relevant to a broad spectrum of potential users, from
clinical chemists to radiologists, all of whom might not be aware of
each other’s literature. Publishing in a radiology journal [28] and a
clinical chemistry journal [29] likely increased the reach and
potential influence of the guidance.
Our experience is that the journal submission and peer review
processes for multiple simultaneous publications can be exhaust-
ing. Some steps can reduce the burden. For example, the guideline
author group might want to nominate an author as corresponding
author to facilitate the coordination process with the various
journals. Before submission it might be useful for the reporting
guideline authors to discuss with prospective journals their interest
in publishing the guidance and the need for all journals to agree a
common text. When submitting the final manuscript the journals
can be asked about their willingness to have a common set of peer
reviewers. Such a move enables the reporting guideline developers
to respond to a single set of peer reviewers rather than separately
to peer reviewers from each journal. Similarly, to ensure
consistency across journals we believe that copy editing should
be limited to spelling, layout, and punctuation, ensuring identical
text across journals. This might be best achieved by having one
lead journal take care of these issues and circulating the copy
edited version across the other journals publishing the article. The
PRISMA Statement, recently published in five journals [30–34],
used these approaches; one journal volunteered to coordinate the
whole editorial process and the other journals used their peer
reviews and copyediting, thus making it more efficient for the
developers and journals alike.
Post-publication Activities
12. Seek and Deal with Feedback and Criticism
It is important to seek feedback and criticism from all
stakeholders regarding the reporting guideline, and we have
outlined several stages by which this can be achieved in the
development process. We recommend that guideline developers
also encourage feedback at any time after publication, either
directly or via the related Web site. Constructive criticism can help
improve the reporting guideline if an update is prepared (see item
18, below). After the CONSORT Statement was originally
published, Meinert [35] provided valuable suggestions on ways
to improve the flow diagram and the clarity of some of the
terminology initially used. These recommendations were incorpo-
rated into the 2001 revision of the CONSORT Statement.
13. Encourage Guideline Endorsement
Some journals, those whose editors initially were involved in the
guideline development, will be eager to support the use of the
reporting guideline. This support can be most readily achieved
when a journal endorses the reporting guideline. However, some
journals have used inconsistent language to describe their
endorsement [36–38], and this vagueness likely diminishes serious
efforts to improve the quality of reporting within journals.
When journals want to endorse a reporting guideline we
recommend that they use strong, clear language of their
expectations of authors, and include this information in their
Instructions to Authors. For example, BioMed Central, the
publisher of 199 open access journals, states, ‘‘We recommend
authors refer to the EQUATOR network website for further
information on the available reporting guidelines for health
research, and the MIBBI Portal for prescriptive checklists for
reporting biological and biomedical research where applicable.
Authors are requested to make use of these when drafting their
manuscript and peer reviewers will also be asked to refer to
these checklists when evaluating these studies’’ (http://www.
biomedcentral.com/bmcdermatol/ifora/).
Reporting guideline developers might also consider developing
some brief text to help journals introduce their guidance to
authors, incorporating the issues discussed above. We also
recommend that when a journal endorses a reporting guideline
they notify the guidance developers. This will help the developers
to document and track all endorsements.
14. Support Adherence to the Guideline
Adherence is not part of developing a reporting guideline.
However, it is central to whether reporting guidelines have their
intended impact. We recommend that guideline developers
consider issues of adherence regarding their reporting guideline,
whether it is a new one or an extension or implementation of an
existing one.
Journal endorsement, while encouraging for guideline develop-
ers, needs to be accompanied by a clear statement of how the
journal expects authors to use the guideline and what level of
adherence is required (e.g., authors of reports of randomized trials
must submit a completed CONSORT checklist along with their
submission). We recommend that journals consider ways to
maximise adherence to reporting guidelines, such as by asking
authors to submit completed checklists and by asking peer
reviewers to use them as part of their review.
15. Evaluate the Impact of the Reporting Guidance
We recommend assessing the impact of any reporting guideline.
Unfortunately, few guidelines appear to have been evaluated to
date [24]. Although the guideline developers will likely want to
evaluate their guidance, and we support such enthusiasm, other
researchers should be also encouraged to conduct these assess-
ments. There are several ways to design and carry out such an
evaluation. Results from the systematic review on CONSORT
evaluations suggest there is considerable room to improve the
designs of these evaluations [39].
16. Develop Web Site
Another implementation strategy is to create a Web site
dedicated to the reporting guideline. It makes the most sense to
develop the Web site before publication so that the address can be
included in the published articles. As a minimum we recommend
including on the Web site the reporting guideline checklist,
statement, ancillary documents such as an E&E, and any
translated versions of the guideline. Also, the list of participants
and funders should be included. The checklist and diagram should
be available as both PDF and DOC files. Related unpublished
documents can be published here too. The Web site is also a useful
venue for alerting readers about emerging issues related to the
guidance and perhaps inviting comments and discussion. We also
recommend including a news section where new information
about the guidance can be posted. Unfortunately, the lack of
funding may impede such valuable additions.
We recommend including an endorser section for the names of
journals and editorial groups endorsing the reporting guideline.
The journals’ Instructions to Authors can be linked to their
endorsement.
The Web site can also provide policy documents regarding the
useoftheguidance.Issuespertainingtocopyright, use ofdocuments
and, if relevant, the permitted use of the guidance logo if there is
one, can be included in this section. Finally, we encourage guideline
developers to consider linking their guideline with the EQUATOR
Network (http://www.equator-network.org).
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After publication of the reporting guideline it is possible that
other researchers will want to translate the reporting guideline into
different languages. The developers should seek to be actively
involved to assure themselves that all translations are completed
appropriately using robust methods including back translation.
18. Update Guideline
As yet few reporting guidelines have been updated, although
most (83%) guideline developers recognize the need to do so [24].
The trigger to update is complex and likely similar to other areas
of research [40]. Chief among these is the body of emerging
literature to inform the currency of the checklist. If this literature is
large and includes policy or empirical evidence it is likely
important to consider updating. For example, recent empirical
evidence [21] on outcome reporting bias led the CONSORT
Group, when preparing CONSORT 2010, to add a checklist item
specifically asking authors to describe any changes made to their
study outcomes between the protocol and final analysis.
We recommend regular consideration of whether or not to
update a reporting guideline and that reporting guideline groups
maintain an executive group that can help make such decisions.
Although it is possible to make frequent (e.g., annual) small updates,
we believe this is not wise and it may even be counterproductive.
Making occasional major updates, with clear version numbers,
seems to be a better approach. We convened a one-day meeting to
update the CONSORT Statement and two-day meeting to update
QUOROM (subsequently published as the PRISMA Statement).
We assume that updating an existing reporting guideline will be
completed by essentially the same team that initially developed the
guidance, although some of the membership may change over
time. That has been our experience from the CONSORT
Statement updates. We also assume that several components of
the initial guideline development process are still in place. For
example, for updating the guideline, the developers would need to
update their existing literature searches.
When considering an update to an existing reporting guideline,
developers should give serious consideration to the seven essential
items (denoted with an {) in Table 1. The development of an E&E
deserves serious consideration when updating a reporting
guideline if none existed before. If there is one, then it too will
need updating (see Box 1). It is helpful to include in the publication
a list of what was changed and why.
We also encourage reporting guideline developers to seriously
consider how best to handle numbering and dates of updates. For
example, the original version of CONSORT did not number the
checklist items. We introduced numbering into the 2001 version,
which meant that we have had to be careful in numbering new
checklist items in the latest (2010) update. We have modified the
numbering slightly. Updating a reporting guideline will influence
checklist items of any published extensions and/or implementa-
tions, and due consideration is required as to how best to handle
these issues.
Discussion
We hope this guidance on how to develop a reporting guideline,
including an 18-step checklist, will fill a gap in the literature and be
of help to potential and practicing developers. While some of the
items are optional, there is a core set of steps we believe necessary
to ensure adequate development of a reporting guideline. In the
future, the EQUATOR Network might consider providing an
appraisal grade for the reporting guidelines included on their
database, reflecting the robustness of the guideline development
process. We also encourage prospective guideline developers to
contact the EQUATOR Network team to inform them about
their work; this might prevent duplication of effort.
We will make the 18-step checklist available on the EQUATOR
Network Web site. We will continue to monitor the literature to
help maintain the guidance, particularly the checklist. Further-
more, we will annually review the need to update the checklist.
While there is increasing evidence that use of reporting
guidelines is associated with improvements in the quality of
reporting health research [37,39,41,42], there is a growing
anecdotal belief that reporting guidelines indirectly have a positive
impact on how researchers design and conduct their research [43].
More formal research is required to substantiate these claims.
Beyond the possible benefit in the design and conduct of health
research, reporting guidelines are now starting to be used as an
adjunct in developing educational courses in the design and
conduct of health research.
Reporting guidelines are currently focused at the end of the
knowledge generation cycle. However, we believe that investiga-
tors would benefit from the knowledge of key principles of health
research reporting and relevant guidelines at the beginning of their
research, having the end in mind. Indeed, guidelines are possibly
equally useful earlier on in this process, and some granting
agencies have acted upon this concept. The SPIRIT initiative is
aimed at providing guidance for writing protocols of RCTs.
Similarly, the UK National Institute of Health Research
developed a research process flowchart (http://www.rdinfo.org.
uk/) to guide researchers in how to start developing a research
project. The flowchart includes reference to reporting guidelines
and encourages researchers to ‘‘consult a relevant guideline in the
early stages of research planning.’’
Given the broad range of health research now covered by
reporting guidelines, funders might start to require prospective
applicants to use some parts of an ‘‘approved’’ reporting guideline
when developing their research application and to include a
completed checklist as part of this process. This might increase the
overall quality of the applications to funders while increasing the
potential return on their investment by emphasizing the importance
of reporting much earlier in the knowledge generation cycle.
Reporting health research in a complete, accurate, transparent,
and timely manner is a shared responsibility of all stakeholders
involved in research funding, conduct, and publication. High-
quality research reports contribute to more efficient translations of
new research findings into clinical practice and help advance
scientific knowledge and patient care. We will all benefit from
these collective efforts.
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